ARTICLE / CLIENT ALERT
Globally (Not So) Mobile Employees: Taxation of Equity Awards in a COVID-19 World
May 4, 2020
Read time: 10 min
The rules relating to the US taxation of equity awards in an international context are often complex and sometimes uncertain. This On the Subject explores how COVID-19-related travel restrictions affect the US taxation of certain equity awards for employees transferred to and from US-based employers.
The US tax rules governing the taxation of equity awards for globally mobile employees are complex and in some cases, uncertain. Among other things, employers must consider the type of award, grant and vesting dates, and sourcing rules to ensure proper reporting and withholding for non-US employees that have worked in the United States. The global Coronavirus (COVID-19) pandemic and its attendant travel restrictions have triggered a panoply of income tax consequences for employers, from simple extensions of filing deadlines to complex considerations such as permanent establishment risk and withholding tax obligations. In addition, the restrictions have caused US multinational businesses to review their existing processes for how they compute and report taxable income for non-US employees working in the United States. This On the Subject addresses an unintended tax consequence important not only for tax executives, but also for corporate human resource and payroll departments: the effect of travel restrictions on the US taxation of equity awards for employees transferred to and from a US-based employer.
Restricted Stock Units and Performance Stock Units
Restricted stock units (RSUs) and performance stock units (PSUs) are commonly used as long-term incentive compensation for executives and key employees. An RSU is an agreement by the employer to issue shares of its stock at certain specified times in the future after the employee has met designated vesting requirements based on continued employment (e.g., 100% vesting upon completing three years of service). A closely related form of grant is a performance stock unit or PSU, which is an agreement to issue shares at certain specified times in the future after meeting specified performance conditions (e.g., attaining a designated level of earnings per share). RSUs and PSUs can be attractive to employers because they reduce the amount of cash employers must pay out in the form of compensation while providing a long-term incentive. These type of awards also avoid income taxation to the employee until shares are received, which can be long after the employee has met all vesting conditions. In the current COVID-19 environment, businesses have been considering issuing additional RSUs and PSUs tied to operational objectives as a way to conserve cash in order to weather the economic storm.
For US citizens performing services in the United States, the rules are relatively straightforward. Structured properly, RSUs and PSUs are not subject to income tax until shares are delivered to the holder. In effect, these awards are an unfunded, unsecured promise to pay compensation, and employees are subject to tax upon receipt of the shares. Unlike shares that are issued up front as restricted stock, RSUs and PSUs are not eligible for an 83(b) election. In addition, depending upon when shares are issued in relation to when the awards vest, there may be restrictions on when the shares may be issued which, if violated, result in federal income tax on vesting, a 20% addition to tax and interest.
The rules relating to the US taxation of RSUs and PSUs (and certain other nonqualified deferred compensation arrangements) in an international context are often complex, daunting and, in some cases, uncertain. During the vesting period, holders of RSUs and PSUs do not have voting rights, nor are they entitled to receive dividends (although dividend equivalent payments are present in some RSU/PSU plans), as the holders do not yet hold actual shares of the company. Depending on each company and the respective plan documents, an employee may receive the net shares or the cash equivalent value of the shares.
RSUs, PSUs and Inbound Assignments
It is common for US multinational corporations to host employees from overseas affiliates for short- to long-term assignments, and such employees may have received RSU or PSU grants before their US assignment began. Identifying the appropriate US taxation of RSUs and PSUs for employees who are not US citizens, lawful permanent residents (i.e., green card holders) or otherwise US income tax residents (i.e., nonresident aliens (NRAs)) requires careful analysis of US sourcing rules. “Multi-year compensation arrangements” can complicate an employer’s US withholding obligations with respect to RSUs and PSUs issued to NRAs. “Multi-year compensation” refers to compensation that is included in the income of an individual in one taxable year but which is attributable to a period that includes two or more taxable years. NRAs may be subject to US income tax on portions of their RSU and PSU income even if they are not considered US income tax residents.
To the extent an NRA physically works in the United States between the date RSU/PSUs were granted and the date they vest, a portion of the value of the RSU/PSUs will be sourced to the United States and therefore be subject to US income taxation. That portion is typically calculated by summing the total number of days the employee provided services in the United States for the employer during the period between the grant date and the vesting date, divided by the total number of days between the grant and the vest date. For example, suppose an NRA employee is granted PSUs on January 1, 2020, with a single vesting date for the entire award on January 1, 2023. The PSUs are worth $100 upon vesting. If the NRA employee works for the employer in the United States during all of 2020 and thereafter provides services in Ireland (from 2022 through December 31, 2023), one-third of the $100 (i.e., $33) upon vesting would be sourced to the United States and therefore be subject to US income tax. To the extent that there are multiple vesting dates under an award, there are often complicated allocation issues, particularly when considered in light of accounting treatment under ASC Topic 718 (Compensation – Stock Compensation).
In some cases, the complex sourcing rules associated with multi-year compensation arrangements lead to employers over-reporting taxable compensation on an employee’s Form W-2 by including foreign source income. In such cases, employees have been successful filing refund claims with the IRS.
Social security withholding is another important consideration for NRA employees who receive multi-year compensatory equity awards. Generally, and with certain exceptions, in the absence of a social security totalization agreement between the United States and the non-US employee’s home country, Federal Insurance Contributions Act (FICA) taxes will apply to the RSU/PSU. Where an NRA is from a totalization agreement country (with the exception of Italy) and is transferred to the United States for a period of five years or less, FICA taxes generally will not apply, provided the foreigner obtains a “certificate of coverage” from her home country and provides it to her US employer. A certificate of coverage confirms that the NRA employee remains subject to her home country’s social security system.
RSUs, PSUs and Outbound Assignments
US tax resident employees who participate in outbound assignments (i.e., transfer to a foreign affiliate of the US corporation) face their own set of unique tax issues regarding RSUs and PSUs. The outbound employees may become tax resident of the country to which they are transferred, and in the absence of an exclusion or exception, US federal income tax income and wage withholding and reporting obligations will remain applicable for the entire award, as the US taxes its citizens and resident aliens on worldwide income.
Limited exclusions exist from US withholding for US citizen and resident employees who work outside the United States on an international assignment. One such exclusion is the US foreign earned income exclusion, which generally permits a US taxpayer to exclude a certain amount of foreign earned income, including RSU/PSU income (for 2020, the amount is $107,600). For a US employer to rely on the foreign income exclusion with respect to withholding on income relating to RSUs and PSUs, the employer must have a reasonable belief that the employee is a qualified individual who is permitted to exclude the equity income from his gross income. A second exception that may be useful for RSU and PSU income applies if a US citizen’s (the exception does not apply to other US income tax residents, including green card holders) income is subject to mandatory non-US tax withholding in the country in which she is employed. Third, a US employer may not be required to withhold on RSU/PSU income to the extent the transferred employee has indicated eligibility for a US foreign tax credit. Finally, if an individual employee is subject to double tax on RSU/PSU income, relief may be available under the terms of an applicable tax treaty. Notwithstanding the applicability of an exclusion, the US employer is required to report the entire amount of the employee’s RSU/PSU income on the employee’s Form W-2 for the applicable tax year.
With regard to FICA withholding, in the absence of a totalization agreement, where a US citizen or permanent resident is employed outside the United States by a US employer (e.g., a branch of a US corporation), US FICA taxes apply and must be withheld from the individual’s income, including RSU/PSU income. If a totalization agreement applies and an individual’s RSU/PSU income would otherwise be subject to non-US social security taxes, US FICA taxes are generally inapplicable if the transfer is for more than five years. Unlike the federal income tax regulations, the FICA regulations provide no basis for apportionment of multi-year compensation such as equity award income.
Tax Equalization
The use of tax equalization agreements is a common method that seeks to manage adverse income tax implications that may arise to globally mobile employees. The primary objective of a tax equalization agreement is to ensure that international assignees are no better or worse off as a result of their home and host country taxes. For example, permanent and temporary income tax distortions may occur as a result of differing income tax rates, income realization and recognition rules, etc. between the home and host country. Some multinational corporations apply tax equalization to all international assignees, while others negotiate tax equalization on a case-by-case basis, typically with executives. To the extent possible, it behooves an employer to project future equalization payments, if any, before sending an employee on an international assignment to avoid future surprises of substantial equalization payments. Moreover, employers that have tax equalization agreements with their employees should consider how their employees’ income tax situations may change because of the inability to travel and how that might impact the size of potential equalization payments.
Introducing COVID-19 into the Mix of Tax Ramifications
Because an employer’s US income and wage withholding obligations on internationally mobile employees generally turns on where the employees provide services, employers should review their existing processes and procedures for computing the US taxable income of non-US employees. In turn, and in the absence of IRS guidance on the issue, employers should consider the effect of COVID-19 travel restrictions on their reporting and withholding obligations, including with regard to RSU/PSU income, if their mobile employees are “stuck” in the United States but continue to work for the company. For example, a foreign employee who intended to leave the United States for his home country (or another non-US host country) but who is unable to leave the United States will require the US company to review and adjust his US withholding obligations to account for the apportionment of additional US source income to that employee when the RSU/PSUs vest. Additionally, employers should review their existing tax processes with respect to option plans that are governed by similar tax rules that govern RSU/PSUs. Accordingly, in light of the current travel restrictions, employers should examine any outstanding and anticipated RSU/PSU vesting and revisit their withholding requirements in advance of RSU/PSUs vesting.
United States: Cartels
ARTICLE
United States: Cartels
May 2020
Read time: 2 min
The latest Cartels Country Comparative Guide 2020 published by The Legal 500, aims to provide a pragmatic overview of Cartel laws and regulations across a variety of jurisdictions. The guide covers information about legislation, conduct of cartel investigations, leniency, settlement, inter-agency cooperation, sanctions, private actions, the appeal process and practitioner points specific to that jurisdiction.
Providing answers to over two-dozen questions, our lawyers break down the Cartels laws and regulations in the United States.

Federal Civil Practice: Chapter 11 – Trial of Federal Cases
ARTICLE
Federal Civil Practice: Chapter 11 – Trial of Federal Cases
May 2020
Read time: 1 min
Copyright permission from Federal Civil Practice (IICLE®, 2020).
Federal Civil Practice: Chapter 9 – Pretrial Procedures and Pretrial Conferences
ARTICLE
Federal Civil Practice: Chapter 9 – Pretrial Procedures and Pretrial Conferences
May 2020
Read time: 1 min
Copyright permission from Federal Civil Practice (IICLE®, 2020).
Federal Civil Practice: Chapter 13 – Class Actions
ARTICLE
Federal Civil Practice: Chapter 13 – Class Actions
May 2020
Read time: 1 min
Copyright permission from Federal Civil Practice (IICLE®, 2020).
CMS Issues FAQs on EMTALA Requirements for Hospitals
ARTICLE / CLIENT ALERT
CMS Issues FAQs on EMTALA Requirements for Hospitals
May 3, 2020
Read time: 6 min
On April 28, 2020, the Centers for Medicare and Medicaid Services (CMS) issued Frequently Asked Questions for Hospitals and Critical Access Hospitals regarding EMTALA (FAQs) as a supplement to the memorandum on the Emergency Medical Treatment and Active Labor Act (EMTALA)-focused Quality, Safety and Oversight Group memorandum analyzed in our On the Subjects here and here.
Hospitals have expressed continued concern regarding their ability to comply with the intricacies of EMTALA in the face of increasing emergency department (ED) visits from individuals with potential Coronavirus (COVID-19) exposure or full-blown disease. The FAQs contain guidance for hospitals regarding which EMTALA requirements are still firmly in place and which allow for more flexibility. Certain of the FAQs will be of particular interest to hospitals.
Patient Access and Constructive Dumping
CMS has emphasized that it is a violation of EMTALA for hospitals with EDs to use signage that presents barriers to individuals, including those who are suspected of having COVID-19, from coming to the ED, or to otherwise refuse to provide an appropriate medical screening examination (MSE) to anyone who has come to the ED for examination or treatment of a medical condition. However, the FAQs confirm that hospitals may use signage to inform individuals about the availability of COVID-19 testing or to provide directions to alternative sites on the hospital’s campus where MSEs are available, such as parking lot test sites. Whether individuals are seen for an MSE at an alternative site or in the ED, they should be logged in where they are seen. Individuals do not need to present to the ED before going to the alternative site.
Hospitals are also permitted to encourage the public to go to off-campus sites to be screened for COVID-19 instead of the hospital. Those off-campus sites must operate in accordance with the state or local pandemic plan, must be identified specifically by the hospital as the location to receive an MSE, and must have the capability and capacity to provide the required MSE. Normally, a hospital may not redirect patients to an off-campus alternative site under EMTALA, but CMS has permitted this action under Section 1135 waiver authority.
Screening and MSEs
All MSEs must still be performed by a qualified medical professional (QMP), which may include physicians, nurse practitioners, physician’s assistants or registered nurses trained to perform MSEs, acting within the scope of their state licensure law and approved by the hospital’s governing body. The FAQS identify that hospitals may request a case-by-case waiver under Section 1135 to allow MSEs to be performed by other personnel, including trained registered nurses or medical staff who were not previously approved by the governing body to perform MSEs.
The FAQs also clarify that patients who present to the hospital solely for the purpose of COVID-19 testing and who do not request treatment of a medical condition do not necessarily require an MSE under EMTALA, with the caveat that if a patient complains of or exhibits any symptoms of a medical condition, then that person should receive an appropriate MSE to determine whether an emergency medical condition exists in accordance with EMTALA
Telehealth
Of key importance given the nature of COVID-19 transmission, the FAQs note that an MSE may be conducted by a QMP via telehealth, if clinically appropriate. However, if a patient is seen by a QMP via electronic two-way technology, and the patient and QMP are considered be in the same location, such as in different areas of hospital buildings, then the QMP is not considered to be furnishing telehealth services under Medicare. These services are not subject to telehealth rules and restrictions and should be reported as in-person services as part of the MSE. The FAQs confirm that use of telehealth to provide evaluation of individuals who have not physically presented to the hospital for treatment does not create an EMTALA obligation.
Patient Transfers
Consistent with EMTALA guidance throughout the COVID-19 pandemic, the FAQs reiterate that hospitals that have exhausted their supply of beds and/or ventilators are still required to provide stabilizing treatment, within their capabilities, to individuals with emergency medical conditions prior to arranging an appropriate transfer. The FAQs provide a grim example of the scope of this obligation, explaining that if a hospital does not have available ventilators, establishing an advanced airway and providing manual ventilation can assist in stabilizing the individual until an appropriate transfer is arranged would be sufficient.
Key Takeaways
CMS continues to roll out waivers and regulatory flexibilities in an effort to assist providers in responding to the COVID-19 pandemic, including waivers and flexibilities related to the complex regulatory scheme around EMTALA. CMS’s latest FAQs identify additional areas where hospitals can take steps to respond to the public health crisis while remaining in compliance. Hospitals struggling with determining how to direct patients for screening, completing screening with limited staff, and the appropriate use of telehealth in an MSE will welcome the guidance provided by the FAQs. However, it is important to be mindful that the basic requirements of EMTALA remain in effect. Hospitals are still expected to provide an MSE to any individual who comes to the ED and requests an examination or treatment of a medical condition. If a patient is determined to have an emergency medical condition, the hospital must still provide stabilizing treatment or an appropriate transfer, as provided by the regulations with flexibilities afforded by the waivers in place.
Hospitals that have additional EMTALA compliance concerns may pursue case-by-case waivers specific to the facts and circumstances they are facing. These waivers may be requested via email at 1135waiver@cms.hhs.gov.

CFIUS Developments: National Security Reviews of Foreign Investments in the United States
ARTICLE / CLIENT ALERT
CFIUS Developments: National Security Reviews of Foreign Investments in the United States
May 1, 2020
Read time: 4 min
In this article, we discuss two notable recent developments in CFIUS reviews: First, CFIUS’s expanded jurisdiction over foreign investments in companies that receive emergency COVID-19-related DPA financing, and second, the filing fee CFIUS now imposes for its reviews.
During the COVID-19 pandemic, while much of the staff of the Committee on Foreign Investment in the United States (CFIUS) has been working remotely, CFIUS has maintained a robust workload. So far, the committee has continued to accept notifications of covered transactions and to conduct timely national security reviews. Among other evolving aspects of CFIUS reviews, two particular recent developments are notable: (1) CFIUS review authority has specifically extended to foreign investments in companies that receive emergency COVID-19-related DPA financing, and (2) CFIUS now imposes a filing fee for its reviews.
CFIUS Jurisdiction Over Foreign Investments in Critical US Infrastructure Includes Businesses Receiving COVID-19-Related DPA Funding
CFIUS, an interagency federal committee chaired by the US Treasury Department, is authorized by Title VII of the Defense Production Act (DPA) to review acquisitions of, and certain investments in, US businesses by foreign parties, in order to determine any threats to US national security. A principal feature of the Foreign Investment Risk Review Modernization Act of 2018 (FIRRMA) was an expansion of CFIUS’s jurisdiction to review certain controlling and non-controlling investments in US businesses involving critical technology, critical infrastructure and sensitive personal data of US citizens. In its new regulations implementing FIRRMA, CFIUS included an exhaustive list of the types of critical infrastructure within its mandate (Appendix A to 31 CFR Part 800), specifically including foreign investments in US businesses that:
Manufacture any industrial resource other than commercially available off-the-shelf items, as defined in 41 USC 104, as amended, or operate any industrial resource that is a facility, in each case, that has been funded, in whole or in part by …. {a} Defense Production Act of 1950 Title III program, as amended (50 USC 4501 et seq.). (31 CFR Part 800 Appendix A)
Based on this critical infrastructure definition, certain foreign investments in US businesses with COVID-19-related DPA Title III contracts would be subject to possible CFIUS review for a period of five years (60 months) following receipt of DPA Title III funding.
CFIUS Now Imposes Filing Fees for Most Reviews
Pursuant to recently published interim regulations, for the first time, CFIUS will impose filing fees for any formal written notice of a “covered transaction” or “covered real estate transaction” filed with CFIUS on or after May 1, 2020. (No fee will be charged for submission of short-form declarations submitted by parties in lieu of full notices.) Applicable fees must be paid before CFIUS will accept a notice and begin a review. Fee amounts will vary depending on the value of the transaction at issue, generally based on the total value of all consideration paid by or on behalf of the foreign party to the transaction. Following is a table of the required fee amounts.
Transaction Value CFIUS Filing Fee
|
$0 to $499,999.99 |
$0 |
|
$500,000 to $4,999,999.99 |
$750 |
|
$5,000,000 to $49,999,999.99 |
$7,500 |
|
$50,000,000 to $249,999,999.99 |
$75,000 |
|
$250,000,000 to $749,999,999.99 |
$150,000 |
|
$750,000,000 + |
$300,000 |
CFIUS has the discretion to grant waivers for the filing fee, in whole or in part, and refunds are available in limited circumstances, including when CFIUS determines the transaction is not a “covered transaction” or “covered real estate transaction.” In cases where CFIUS allows parties to withdraw and refile a notice, the filing fee would not need to be paid again unless a material change to the transaction has occurred or the filing contained a material inaccuracy or omission.

CMS Updates COVID-19 Guidance for MA Organizations and Part D Sponsors, Addresses the Status of Telehealth Visits for Risk Adjustment
ARTICLE / CLIENT ALERT
CMS Updates COVID-19 Guidance for MA Organizations and Part D Sponsors, Addresses the Status of Telehealth Visits for Risk Adjustment
May 1, 2020
Read time: 9 min
Since early March 2020, the Centers for Medicare and Medicaid Services (CMS) has released a steady stream of guidance to Medicare Advantage Organizations (MAOs) and Part D sponsors in connection with the Coronavirus (COVID-19) outbreak. CMS recently compiled much of this guidance in a memorandum published on April 21, 2020, which revised prior guidance released on March 10, 2020. CMS also issued a new memorandum addressing the status of telehealth visits for risk adjustment, which was prompted by the expansion of telehealth but may extend beyond the COVID-19 emergency. This new guidance describes additional flexibilities CMS is granting MAOs and Part D sponsors, coverage requirements mandated by recent changes in law, and obligations MAOs and Part D sponsors have under existing program rules.
Medicare Advantage Organizations
Additional MAO Flexibilities
CMS identified numerous areas where it is exercising its enforcement discretion to permit MAOs to take actions that would otherwise be inconsistent with current program regulations, including certain benefit enhancements, lengthened member termination grace periods, and flexibilities specific to special needs plans (SNPs).
Benefit Enhancement and Telehealth. CMS will exercise its enforcement discretion to allow MAOs to:
- Make mid-year changes to their benefit packages (e.g., expanding covered benefits and reducing cost-sharing). The changes must (1) be provided in connection with the COVID-19 outbreak, (2) benefit members and (3) be provided uniformly to all similarly situated members. CMS cited meal delivery and medical transportation services to promote social distancing efforts as examples of accepted benefits.
- Provide enrollees access to Medicare Part B services via telehealth in any geographic area and from beneficiaries’ homes. This flexibility is irrespective of the scope of the telehealth benefit the MAO filed and CMS approved.
- Waive or reduce cost-sharing for members affected by the outbreak. The waiver or reduction must be consistently provided to all similarly situated enrollees and must be “tied to the outbreak.” As discussed below, separate legislation prohibits MAOs from charging cost-sharing for certain COVID-19-related services.
Risk Adjustment of Telehealth Visits. In separate guidance released on April 10, 2020, CMS stated that MAOs may submit diagnoses for risk adjustment that are from telehealth visits “when those visits meet all criteria for risk adjustment eligibility, which include being for an allowable inpatient, outpatient, or professional service, and from a face-to-face encounter.” CMS specified that diagnoses may meet the face-to-face requirement when provided using an interactive audio and video telecommunications system that permits real-time interactive communication. This policy is effective for both Risk Adjustment Processing System and Encounter Data System submissions. Although the memo initially references the expansion of telehealth due to COVID-19, CMS did not limit the application of its stated interpretation to any particular start or end date. As such, telehealth visits that occurred prior to the COVID-19 context may also be considered “face-to-face” visits for risk adjustment purposes. MAOs that provided coverage for telehealth prior to the COVID-19 emergency may wish to evaluate whether those visits qualify for risk adjustment.
Involuntary Disenrollment Timeframes. MAOs may delay involuntary disenrollment of enrollees who are temporarily absent from the service area for more than six months because of the COVID-19 emergency.
SNP Flexibilities. CMS is also exercising its enforcement discretion for SNPs, including:
- Permitting SNPs to delay disenrollment of enrollees who are losing special needs status and cannot recertify SNP eligibility because of the COVID-19 emergency
- Acknowledging that SNPs may need to deviate from their model of care to ensure that enrollees and providers are protected from COVID-19, and “considering” the special circumstances created by the outbreak when conducting model of care monitoring and oversight.
Other Enforcement Discretion. CMS also recognized that there might be other circumstances where an MAO may decide that it is “reasonable and necessary” to take actions that “do not fully comply with program requirements” in order to provide basic benefits while protecting enrollees from the spread of COVID-19. CMS stated that it will “consider the special circumstances presented by the COVID-19 outbreak when conducting monitoring or oversight activities.”
MAO Required Actions
In addition to providing guidance on new flexibilities, CMS advised MAOs of new requirements and reminded MAOs of their existing obligations triggered by declared emergencies.
COVID-19 Coverage Mandates. Pursuant to the Families First Coronavirus Response Act and the Coronavirus Aid, Relief, and Economic Security (CARES) Act, MAOs cannot impose cost-sharing or utilization management requirements (such as prior authorization) on members receiving the following:
- Clinical laboratory tests for the detection of SARS-CoV-2 or the diagnosis of the virus that causes COVID-19 and the administration of such tests
- COVID-19 testing-related services
- COVID-19 vaccines and the administration of such vaccines.
Section 1135 Waivers. The Secretary issued a Section 1135 waiver allowing CMS to authorize Medicare Administrative Contractors to pay for Part C covered services and seek reimbursement from MAOs for those services retrospectively. CMS noted, however, that to date it has not authorized Medicare Administrative Contractors to take this action.
On March 13, 2020, CMS exercised its authority under section 1135 to waive and modify requirements related to Medicare Advantage appeals and grievances:
- Timeframes for filing appeals and requests for additional information are extended.
- Appeals must be processed even with incomplete Appointment of Representation forms, but communicated only to the beneficiary.
- Requests for appeals that do not meet the required elements will be processed using the information available.
Disaster and Emergency Regulations. CMS reminded MAOs that pursuant to 42 CFR § 422.100(m), they have certain obligations during disasters and emergencies to ensure access to benefits. Qualifying emergencies are currently in effect for all 50 states, the District of Columbia and the Territories. For the duration of the emergency declaration, an MAO must:
- Cover Medicare Parts A and B services and supplemental Part C benefits rendered at non-contracted facilities, subject to § 422.204(b)(3)’s requirements that facilities have participation agreements with Medicare
- Waive requirements for gatekeeper referrals
- Provide the same cost-sharing for enrollees as if the service was furnished at a contracted facility
- Make changes that benefit enrollees effective immediately, without the 30-day notification requirement at § 422.111(d)(3).
Part D Sponsors
CMS also noted several new flexibilities for Part D sponsors, summarized new statutory requirements to ensure access to drugs during the emergency, and reiterated existing requirements triggered by the outbreak.
New Flexibilities. CMS encouraged Part D sponsors to take actions they “deem reasonable and necessary” to keep members and employees safe, while also ensuring access to drugs. CMS acknowledged that some such actions may not “fully comply with program requirements” and stated that the agency will “consider the special circumstances presented by the COVID-19 outbreak when conducting monitoring or oversight activities.” To that end, CMS announced that it is exercising its enforcement discretion during the COVID-19 emergency to permit Part D sponsors to:
- Dispense solid oral doses of brand-name drugs to enrollees residing in long-term care facilities for more than 14-day increments at a time
- Waive Part D medication delivery documentation and signature log requirements, including in the case of opioids
- Relax “to the greatest extent possible” prior authorization requirements, where appropriate
- Suspend plan-coordinated pharmacy audits.
Extended Drug Access During the Emergency. CMS summarized several requirements intended to ensure drug access. Specifically, Part D sponsors must:
- Relax their “refill-too-soon” edits if necessary to ensure access to covered Part D drugs except as limited by safety edits. CMS notes that relaxed refill-too-soon edits are safety edits for the purpose of § 3714 of the CARES Act.
- Allow members to obtain the total day supply prescribed (up to 90 days) if requested by the enrollee, subject to applicable safety edits and utilization management requirements.
Despite the emphasis on expanded access, CMS explicitly noted that Part D sponsors may continue or begin to implement safety edits. With respect to opioid safety edits, CMS stated that Part D sponsors “are expected” to apply existing point-of-sale safety edits but are “encouraged” to waive requirements for pharmacist consultation with the prescriber to confirm intent.
Existing Requirements and Flexibilities for Emergency Access. CMS reminded Part D sponsors of Prescription Drug Benefit Manual provisions intended to ensure adequate emergency access for enrollees. Specifically, Part D sponsors:
- Must ensure that enrollees who cannot reasonably be expected to obtain covered Part D drugs at a network pharmacy have adequate access to covered Part D drugs dispensed at out-of-network pharmacies (subject to normal cost sharing and charges)
- Must follow existing CMS guidance should a drug shortage arise
- May relax any plan-imposed policies that would discourage certain methods of delivery, such as mail or home delivery, for enrollees who cannot physically access a retail pharmacy (e.g., because of a quarantine) and retail pharmacies that provide such services
- May waive prior authorization, as long as they do so consistently, in the event that Part D drugs are identified to treat or prevent COVID-19.
MAOs and Part D Sponsors
Involuntary Disenrollment. CMS encouraged MAOs and Part D sponsors to eliminate or relax any existing policies regarding enrollee disenrollment for non-payment of premiums. CMS encouraged plans to lengthen the mandatory grace period, at a minimum.
Marketing and Communications. CMS indicated that COVID-19 messages to members regarding information on precautions and the public health emergency “would almost invariably be communications” and thus would not require Health Plan Management System (HPMS) submission and review prior to dissemination.
Discontinuation of Enforcement Discretion. Once the outbreak has subsided, CMS will notify MAOs and Part D sponsors through HPMS that CMS is ending its enforcement discretion.
Business Continuity Plans. CMS reminded MAOs and Part D sponsors that existing regulations require them to have business continuity plans to minimize disruptions during emergencies.

Third Circuit: “Rigorous Analysis” Required for Class Certification in Antitrust Cases
ARTICLE / CLIENT ALERT
Third Circuit: “Rigorous Analysis” Required for Class Certification in Antitrust Cases
May 1, 2020
Read time: 8 min
The US Court of Appeals for the Third Circuit recently concluded in In re Lamictal Direct Purchaser Antitrust Litigation that a district court’s reliance on average prices to determine class-wide impact was insufficient. Instead, courts must conduct a rigorous analysis of the facts, evidence and expert testimony at the class certification stage of litigation.
On April 22, 2020, the US Court of Appeals for the Third Circuit overturned a district court decision certifying a class of direct purchaser plaintiffs without undertaking a rigorous analysis to resolve factual disputes, assess competing evidence or weigh conflicting expert testimony. See In re Lamictal Direct Purchaser Antitrust Litig., No. 19-1655 (3d Cir. April 22, 2020). The Third Circuit concluded that the district court impermissibly found that average prices were generally acceptable to demonstrate common proof of antitrust injury necessary for satisfying the predominance requirement of class certification. The Third Circuit vacated and remanded the district court’s decision. This case is a reminder that courts must conduct a rigorous analysis of the facts, evidence and expert testimony at the class certification stage of litigation, even where factual disputes at issue may overlap with the merits of a case.
The Lamictal case stems from a so-called reverse-payment settlement agreement between GlaxoSmithKline (GSK) and Teva Pharmaceuticals concerning generic lamotrigine tablets. GSK sold branded Lamictal tablets. After Teva filed an application for approval to sell lamotrigine tablets (a generic version of Lamictal), GSK initiated litigation against Teva alleging that its generic lamotrigine tablets infringed on GSK’s patents for Lamictal. GSK and Teva eventually settled the litigation under an agreement that permitted Teva to begin selling generic lamotrigine six months before GSK’s patents expired, but later than if Teva had succeeded in defeating GSK’s patent infringement claims. In exchange, GSK promised not to launch its own generic version of Lamictal (known as an authorized generic).
Thereafter, a group of wholesalers that directly purchased Lamictal or lamotrigine tablets filed a class action claiming that GSK and Teva suppressed competition and artificially inflated prices for generic lamotrigine tablets by agreeing that GSK would not launch an authorized generic. A district court certified the class of direct purchaser plaintiffs, which GSK and Teva appealed to the Third Circuit.
The Third Circuit reviewed the district court’s class certification order for abuse of discretion. An abuse of discretion occurs “if a district court’s decision rests on a clearly erroneous finding of fact, an errant conclusion of law, or an improper application of law to fact.” A district court “errs as a matter of law when it fails to resolve a genuine legal or factual dispute relevant to determining” whether the requirements of Federal Rule of Civil Procedure 23 class certification are met. Because the Third Circuit reviewed the legal standards applied by the district court, the Third Circuit reviewed the district court’s decision de novo.
To certify a class under Rule 23, a proposed class must meet the requirements of Rule 23(a) and (b). Rule 23(a) requires the class to satisfy numerosity, commonality, typicality and adequacy criteria. The relevant portion of 23(b) in Lamictal requires that common questions of law and fact predominate over individualized issues, and that the class action is the superior method for adjudication. GSK and Teva appealed the district court’s predominance finding, arguing that the proposed class was not able to demonstrate that its legal claim is capable of proof common to the class at trial.
The Third Circuit reasoned that the court must undertake a “rigorous analysis” in considering the predominance requirement. The Third Circuit explained that such “rigorous analysis” involves:
- Determining whether facts underlying the Rule 23 requirements are met by a preponderance of the evidence,
- Resolving disputed factual or legal issues relevant to class certification and
- Weighing relevant evidence and arguments, including competing expert testimony.
Regarding the preponderance inquiry, on appeal the direct purchaser plaintiffs argued that predominance is satisfied where plaintiffs can demonstrate that antitrust injury is capable of common proof at trial, but that class-wide injury need not be conclusively proven. The plaintiffs further submitted that class-wide impact is capable of common proof unless “no reasonable juror could have believed” the common proof at trial. See Tyson Foods v. Bouaphakeo, 136 S. Ct. 1036 (2016). The Third Circuit rejected the direct purchaser plaintiffs’ argument. It found that the plaintiffs erroneously relied on a standard concerning the accuracy and representativeness of sample data that was confined to Fair Labor Standards Act (FLSA) cases. The Third Circuit held that the correct standard to apply for class determinations outside the FLSA context is the Third Circuit’s longstanding rule that “a putative class must demonstrate that its claims are capable of common proof at trial by a preponderance of the evidence.” See In re Hydrogen Peroxide Antitrust Litig., 552 F.3d 305 (3d Cir. 2009).
Next, the Third Circuit turned to whether the direct purchaser plaintiffs’ claims of antitrust injury are capable of common proof at trial. The plaintiffs’ expert opined that antitrust injury was capable of common proof because evidence common to the proposed class showed that the prices paid for lamotrigine tablets by all or almost all of the class members were affected by the agreement between GSK and Teva. The plaintiffs’ expert created a model relying on an average hypothetical price that purported to show the price each direct purchaser plaintiff would have paid absent the GSK-Teva settlement. The plaintiffs’ expert relied on economic literature concerning the average price of generic drugs, Teva’s internal general pricing forecasts and transactional sales data.
The defendants’ expert criticized the direct purchaser plaintiffs’ model for relying on an average hypothetical price and assuming that an “aggregate actual price” applied to the entire class. This model failed to account for individual negotiations, Teva’s preemptive pricing strategy or GSK’s contracting strategy. The defendants’ expert further argued that the plaintiffs’ model failed to acknowledge the differing prices that each purchaser paid, including accounting for varying rebates or discounts. The model also should have relied on drug-specific prices rather than general forecasting documents discussing average prices. Thus, the defendants’ expert argued that the direct purchaser plaintiffs’ model masked meaningful variation in the prices that class members paid. According to the defendants’ expert, evidence showed that up to one-third of the class members paid prices for generic lamotrigine tablets that were the same or lower than the generic prices that some class members would have paid had GSK launched an authorized generic. The defendants’ expert argued that such considerations require an individualized inquiry rather than proof common to the class.
The Third Circuit held that the district court abused its discretion when it assumed that average prices were acceptable to satisfy the Rule 23(b) predominance requirement without first undertaking a rigorous analysis. The Third Circuit acknowledged that whether averages are acceptable turns on several factual predicates disputed by the parties, as well as competing legal theories. A district court “must formulate a prediction as to how some specific issues will play out in order to determine whether common or individual issues predominate in a given case.”
In the instant case, the district court failed to address “the multi-leveled microeconomic analysis of what each [d]efendant would or would not have possibly done in the but-for world.” Instead, the district court focused on whether GSK’s contracting strategy created individualized issues sufficient to defeat predominance. The Third Circuit further reasoned that the district court’s lack of analysis may have been due to a mistaken assumption that antitrust injury occurred the moment that GSK and Teva reached their reserve settlement agreement. This assumption, however, fails to account for the defendants’ argument that Teva preemptively lowered its prices for generic lamotrigine tablets after learning about GSK’s contracting strategy for Lamictal. The district court should have resolved this contested fact and other factual disputes by a preponderance of the evidence, assessed competing evidence and weighed the expert analysis before finding that average prices were acceptable and that the predominance requirement was satisfied.
Finally, the Third Circuit further justified remanding the district court’s order because its class certification analysis conflated antitrust injury with damages. During class certification, the direct purchaser plaintiffs presented average pricing analyses to show injury—i.e., that each wholesaler paid inflated prices for lamotrigine tablets—in addition to damages. This error was significant given that the Third Circuit applies a more lenient standard for calculating damages than it does for injury.
The Lamictal case serves as a reminder to antitrust litigants and others that reliance on average prices to show common antitrust injury creates significant risk to class certification. While in rare instances average prices might be sufficient to meet the predominance requirement in an antitrust case, courts should also review the evidence, resolve factual disputes and consider conflicting expert testimony. Litigants should ensure that the appropriate standards are applied for each portion of the class certification analysis, particularly as they relate to antitrust injury and antitrust damages.

CMS Announces Immediate COVID-19 Reporting Requirements Applicable to Long Term Care Facilities
ARTICLE / CLIENT ALERT
CMS Announces Immediate COVID-19 Reporting Requirements Applicable to Long Term Care Facilities
Updated: May 8, 2020
Read time: 9 min
As previously reported, President Trump’s Opening Up America plans introduce measures to slowly ease business and social restrictions and require enhanced testing and reporting of the incidence of novel Coronavirus (COVID-19) incidences in long term care facilities (LTCFs), including skilled nursing facilities and nursing facilities. On May 8, 2020, the Centers for Medicare & Medicaid Services (CMS) published an interim final rule with comment period (85 Fed. Reg. 27550) containing certain revisions to 42 C.F.R. § 483.80. These revisions obligate LTCFs to report information related to COVID-19 cases among facility residents and staff. In the interest of public health urgency, CMS is waiving the opportunity for the public to comment on these new reporting requirements, and they became effective immediately upon publication.
Under the Social Security Act and existing regulations, LTCFs are required to develop and maintain an infection control plan that protects the health and safety of residents, staff, visitors and the general public (42 C.F.R. § 483.80). The infection control plan must balance the obligation to provide a safe, sanitary and comfortable environment for residents while also taking efforts to prevent, identify, report, investigate, and control infections and communicable diseases. This includes a requirement for LTCFs to prepare written surveillance standards to identify communicable diseases before they can be transmitted to other residents, staff, volunteers, visitors or members of the community.
Recognizing the role of that rapid reporting has in surveillance, CMS added several new reporting obligations to enhance LTCFs’ efforts to monitor and prevent communicable diseases:
- New provision 42 C.F.R. § 483.80(g)(1): LTCFs are be required to electronically report certain information related to COVID-19 that will be used to monitor trends in infection rates and to allow public health authorities to establish policies, including:
- Suspected and confirmed COVID-19 infections among residents and staff, including residents previously treated for COVID-19.
- Total deaths (including total COVID-19-related deaths) among residents and staff.
- Personal protective equipment and hand hygiene supplies in the facility.
- Ventilator capacity and supplies in the facility.
- Resident beds and resident census.
- Access to COVID-19 testing while the resident is in the facility.
- Staffing shortages.
- Other information that the Secretary of Health and Human Services deems necessary.
- New provision 42 C.F.R. § 483.80(g)(2): No less than weekly, LTCFs must report the above-listed information to the Centers for Disease Control (CDC) National Healthcare Safety Network (NHSN) following a standard electronic reporting format. This information will be shared with CMS and will be made publicly available in a file accessible at https://data.cms.gov. pursuant to any Freedom of Information Act requests. This new requirement does not eliminate LTCFs’ existing obligation to comply with state and local COVID-19 requirements.
- New provision 42 C.F.R. § 483.80(g)(3): LTCFs must inform residents, their representatives and families of residents of any confirmed or suspected COVID-19 cases in the facility among residents and staff. These notifications may be issued through mail, listserv or website postings, recorded telephone messages, or other convenient mass communication efforts, but they must occur by 5:00 p.m. on the next calendar day following the occurrence of either of the below:
- A singled confirmed infection of COVID-19 in a resident, staff or volunteer
- Three or more residents or staff with new respiratory symptoms that emerge within 72 hours of each other.
- Facilities also must provide cumulative updates to residents, their representatives and families by 5:00 p.m. on the next calendar day following any subsequent occurrences of the above reportable events. CMS emphasizes the importance of empowering residents to be informed participants in their care while reassuring residents that the facility is taking meaningful steps to mitigate risk of COVID-19 to the extent practicable. Reports should not include any personally identifiable information, and any messaging should address the LTCF’s efforts to prevent or mitigate transmission, including any impact such efforts have on the LTCF’s daily operations, visitation policies or group activities.
The CDC NHSN COVID-19 reporting module for LTCFs is now populated with instructions for LTCFs to submit reports. The reporting module focuses on four pathways: (i) resident impact and facility capacity, (ii) staff and personnel impact, (iii) supplies and personal protective equipment, and (iv) ventilator capacity and supplies. CDC encourages LTCFs to monitor the NHSN website for further instructions, including a schedule for upcoming training sessions. LTCFs must submit their first set of data by 11:59 pm on May 17, 2020. Compliance requires at least one data submission every seven days. The new reporting regulations supplement LTCFs’ existing responsibility to report possible incidents of communicable disease and infections to other parties as specified in the LTCF’s infection prevention and control program, including compliance with state and local reporting requirements for COVID-19.
Revised COVID-19-Focused Survey for Nursing Homes; Penalties; FAQs
Related to the new LTCF reporting obligations, on May 6, 2020, CMS released a Quality, Safety & Oversight Group memorandum, QSO-20-29-Nursing Homes, (QSO Memo) that updates the “COVID-19 Focused Survey for Nursing Homes” utilized by federal and state survey agencies. Although LTCF survey activities continue to be limited to immediate jeopardy situations that involve urgent patient safety threats and infection control issues, surveyors are instructed to begin evaluating LTCFs’ reporting compliance immediately. To that end, CMS added two new deficiency tags that will be used to cite non-compliance. A deficiency citation at F884 will be cited offsite by federal inspectors if a facility fails to meet its obligation to report data to CDC via NHSN in a timely manner. A deficiency citation at F885 will arise if onsite inspections by state or federal surveyors find noncompliance with a facility’s obligations to report confirmed or suspected COVID-19 infections to residents, their representatives and families.
CMS has made clear that it views these obligations as high-priority compliance items and will impose civil monetary penalties (CMPs) upon facilities that fail to report data to NHSN. Although non-compliant facilities will receive a deficiency citation at F884, CMS is putting in place an effective three-week grace period before facilities will be subject to a CMP for their failure to report. The specific timeline for reporting set forth in the QSO Memo, and the unusual mechanism for calculating the potential CMPs that will apply to facilities that fail to report, are set forth below:
- May 8 – May 24, 2020: Initial two-week grace period for LTCFs to register with NHSN and to begin reporting.
- Week Three (Ending May 31, 2020): Facilities that fail to submit reports by 11:59 pm on May 31 will receive a warning letter notifying the facilities of their reporting obligation.
- Week Four (Ending June 7, 2020): Facilities that are non-compliant with the reporting obligations will have imposed upon them a CMP of $1,000, representing a one-day failure to report that week’s required information.
- Subsequent Weeks: Facilities that are non-compliant with the reporting obligations will incur the baseline CMP of $1,000. If this non-compliance represents a second (or more) instance of failing to report, CMS will also impose an additional one-day CMP of $500 for each cumulative week’s failure to report timely. For example, if a facility fails to report during Week Four and Week Five, reports successfully during Week Six, and fails again to report during Week Seven, the CMP imposed in Week Seven will be $2,000 (representing the $1,000 baseline CMP and an additional $500 for each of the two weeks where the facility failed to report). The cumulative penalties would be as follows:
- Week Four: $1,000 CMP
- Week Five: $1,500 CMP (total penalties of $2,500)
- Week Six: no penalty (total penalties of $2,500)
- Week Seven: $2,000 CMP (total penalties of $4,500)
Facilities’ reporting obligations will continue until CMS notifies stakeholders that reporting is no longer required. CMS has not communciated how this notification will be disseminated.
The QSO Memo also included several answers to frequently asked questions. Some of the most pertinent guidance is as follows:
- State and local health departments may submit data on an LTCF’s behalf after the LTCF has enrolled with NHSN. Data can also be batched for submission on behalf of multiple facilities.
- The presence of COVID-19 and reporting of same will not necessarily result in a citation for infection control violations. Surveyors will continue to survey only for immediate jeopardy situations, and citations for infection control and prevention non-compliance will arise if observed in such surveys.
- Facilities have the ability to report cases retroactively and are encouraged to do so, but CMS will not require retrospective reporting of cases that arose prior to May 8, 2020.
- For the purposes of reporting clusters of three or more staff experiencing new respiratory symptoms within 72 hours of each other, “staff” includes employees, consultants, contractors, volunteers and caregivers who provide care and services to residents in the facility, including nurse aides who have not yet completed a Nurse Aide Training and Competency Evaluation program but who are providing services to residents.
Key Takeaways
LTCFs are now required to report COVID-19-related information to the CDC, residents, and residents’ representatives and family members. Failure to do so will result in citations and could result in CMPs. LTCF administrators and management should (i) identify the staff responsible for coordinating required reports and overseeing resident and family reporting obligations, (ii) develop or reinforce existing policies and processes for data gathering and reporting of the information identified in the new regulatory provisions, (iii) enroll in the CDC NHSN COVID-19 reporting module, (iv) familiarize themselves with instructions for report submissions and reporting logistics, and (v) work closely with counsel to develop resident and family reporting pathways in compliance with the new regulations and survey guidance.
